Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-03-29, Stock:JNJ, The news for the past five days is as follows:
2018-03-22: NEWS1: Is Geron Corporation Stock Still a Strong Buy?.NEWS2: Is Geron Corporation Stock Still a Strong Buy?.NEWS3: Is Geron Corporation Stock Still a Strong Buy?.NEWS4: 4 Reasons Why Glaxo (GSK) Stock Can be a Great Pick in '18.NEWS5: 4 Reasons Why Glaxo (GSK) Stock Can be a Great Pick in '18.NEWS6: MARKETS: Forget 3 rate hikes in 2018—Bill Gross says 2 max.NEWS7: VIG, GASX: Big ETF Outflows.NEWS8: VIG, GASX: Big ETF Outflows.NEWS9: 30 Most Obese Countries In The World in 2018: Biggest Anti-Obesity Drug Markets.NEWS10: Biotech Winners And Losers From Congress' Latest Funding Bill.NEWS11: How Gilead’s HCV Drugs Performed in 2017.NEWS12: Facebook’s Zuckerberg had 15 minutes to respond to privacy crisis — he took four days.NEWS13: See what the IHS Markit Score report has to say about Johnson & Johnson..NEWS14: How Gilead Sciences’ TAF-Containing HIV Drugs Performed.NEWS15: Bloomberg Big Decisions: Johnson & Johnson CEO Alex Gorsky.
2018-03-23: NEWS1: Pharma Stock Roundup: ABBV&apos;s Rova-T Disappoints, J&J Unit Gets Buyout Offer.NEWS2: Commentary: 5 Questions Facebook’s Leaders Still Need to Face.NEWS3: Pfizer is having a tough time selling its consumer health care business.NEWS4: Why Geron Corp. Is Rallying 10% Today.NEWS5: Why Geron Corp. Is Rallying 10% Today.NEWS6: Dow 30 Stock Roundup: Nike Beats, J&J Gets $2.1B Offer for Diabetes Device Unit.NEWS7: Dow 30 Stock Roundup: Nike Beats, J&J Gets $2.1B Offer for Diabetes Device Unit.NEWS8: VT, JPM, JNJ, CSCO: ETF Inflow Alert.NEWS9: VT, JPM, JNJ, CSCO: ETF Inflow Alert.NEWS10: Why Geron Corp. Is Rallying 10% Today.NEWS11: These 12 Drugs Launching In 2018 Are Headed For Blockbuster Status.NEWS12: The Recent Bid for Johnson & Johnson’s LifeScan Unit.NEWS13: Better Buy: Johnson & Johnson vs. Merck.NEWS14: Better Buy: Johnson & Johnson vs. Merck.NEWS15: Dow 30 Stock Roundup: Nike Beats, J&J Gets $2.1B Offer for Diabetes Device Unit.NEWS16: Better Buy: Johnson & Johnson vs. Merck.NEWS17: AbbVie (ABBV) Stock Falls on Weak Lung Cancer Study Outcome.NEWS18: AbbVie (ABBV) Stock Falls on Weak Lung Cancer Study Outcome.NEWS19: How Gilead Sciences’ Ranexa, AmBisome, Zydelig, and Vosevi Performed.NEWS20: See what the IHS Markit Score report has to say about Johnson & Johnson..NEWS21: How Gilead’s Viread, Complera, and Letairis Performed.NEWS22: AbbVie (ABBV) Stock Falls on Weak Lung Cancer Study Outcome.NEWS23: Inside J&J's Effort to Cut Costs and Drive Integration at Ad Firms WPP and Omnicom.
2018-03-26: NEWS1: 'Fair, equitable trade' is in everyone's best interests: ....NEWS2: Open trade is ultimately in 'everyone's best interest,' Johnson & Johnson CEO says.NEWS3: CNBC Transcript: Alex Gorsky, Chairman & CEO, Johnson & Johnson.NEWS4: JNJ INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Johnson & Johnson Investors.NEWS5: Don't Worry, Pfizer Isn't Out of Options for Its Consumer Health Division Just Yet.NEWS6: Don't Worry, Pfizer Isn't Out of Options for Its Consumer Health Division Just Yet.NEWS7: A Biotech Collapses: Is Buying Now 'Futile'?.NEWS8: Don&apos;t Worry, Pfizer Isn&apos;t Out of Options for Its Consumer Health Division Just Yet.NEWS9: Why Protagonist Therapeutics, Inc. Is Imploding Today.NEWS10: Why Protagonist Therapeutics, Inc. Is Imploding Today.NEWS11: Glaxo Drops Bid for Pfizer Unit, Shingrix Gains EU/Japan Nod.NEWS12: Glaxo Drops Bid for Pfizer Unit, Shingrix Gains EU/Japan Nod.NEWS13: Why Protagonist Therapeutics, Inc. Is Imploding Today.NEWS14: Novartis Gets Positive CHMP Opinion on Biosimilar Remicade.NEWS15: Novartis Gets Positive CHMP Opinion on Biosimilar Remicade.NEWS16: Is Pfizer's Best Option Now a Consumer Healthcare Spinoff?.NEWS17: Is Pfizer's Best Option Now a Consumer Healthcare Spinoff?.NEWS18: The Zacks Analyst Blog Highlights: AbbVie, J&J, Heron Therapeutics, Roche and Pfizer.NEWS19: The Zacks Analyst Blog Highlights: AbbVie, J&J, Heron Therapeutics, Roche and Pfizer.NEWS20: Better Stock: Verizon Communications Inc. (VZ) vs. Johnson & Johnson (JNJ).NEWS21: Better Stock: Verizon Communications Inc. (VZ) vs. Johnson & Johnson (JNJ).NEWS22: Is Pfizer&apos;s Best Option Now a Consumer Healthcare Spinoff?.NEWS23: See what the IHS Markit Score report has to say about Johnson & Johnson..NEWS24: Yahoo Finance Live: Market Movers - Mar 26, 2018.NEWS25: The Zacks Analyst Blog Highlights: AbbVie, J&J, Heron Therapeutics, Roche and Pfizer.NEWS26: Better Stock: Verizon Communications Inc. (VZ) vs. Johnson & Johnson (JNJ).
2018-03-27: NEWS1: 3 Dividend Stocks Ideal for Retirees.NEWS2: 3 Dividend Stocks Ideal for Retirees.NEWS3: Platinum Equity lines up US$1.9 billion of debt for J&J diabetes care unit bid.NEWS4: 10 Biggest Product Recalls of All Time.NEWS5: 10 Biggest Product Recalls of All Time.NEWS6: INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Johnson & Johnson of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of April 9, 2018 - JNJ.NEWS7: Platinum Equity lines up US$1.9bn of debt for J&J diabetes care unit bid.NEWS8: NYSE trader: Don't expect crazy volatility due to end-of-quarter portfolio rebalancing—but Facebook could get dumped.NEWS9: Why Geron Corporation Stock Is Crashing Today.NEWS10: Commentary: How Facebook’s Response Ignited the Cambridge Analytica Scandal.NEWS11: 3 Chart Patterns That Suggest Prices Are Headed Lower.
2018-03-28: NEWS1: Top Research Reports for Johnson & Johnson, Intel and Procter & Gamble.NEWS2: Top Research Reports for Johnson & Johnson, Intel and Procter & Gamble.NEWS3: Top Research Reports for Johnson & Johnson, Intel and Procter & Gamble.NEWS4: How Did Novartis Perform in 4Q17 and Full-Year 2017?.NEWS5: 3 Dow Stocks to Buy Amid Tech Selloff.NEWS6: 3 Dow Stocks to Buy Amid Tech Selloff.NEWS7: FDA working on a "dozen" policies to boost copycat biotech drugs.NEWS8: AbbVie a Top Ranked SAFE Dividend Stock With 4.2% Yield (ABBV).NEWS9: AbbVie a Top Ranked SAFE Dividend Stock With 4.2% Yield (ABBV).NEWS10: In Battle To Cut Drug Prices, Outcome-Based Pricing Carries Big Risks For Biopharma.NEWS11: Big Pharma&apos;s billion-dollar scramble to invest in start-ups to fuel innovation.NEWS12: Big Pharma's billion-dollar scramble to invest in start-ups to fuel innovation.

Answer: Rise